A Phase 3 interventional study of Tislelizumab and Placebo in Gastric, or Gastroesophageal Junction Adenocarcinoma, sponsored by BeiGene. Completed at 149 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg of tislelizumab intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-fluorouracil (5-FU) on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with 200 mg tislelizumab, with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.
Drug: Tislelizumab · Drug: Cisplatin · Drug: Oxaliplatin · Drug: Capecitabine · Drug: 5-Fluorouracil
Participants received placebo intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-FU on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with placebo with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.
Drug: Placebo · Drug: Cisplatin · Drug: Oxaliplatin · Drug: Capecitabine · Drug: 5-Fluorouracil
200 mg intravenously (IV) on Day 1 of each 21-day cycle
Also known as: BGB-A317, TEVIMBRA®
Placebo to match tislelizumab IV on Day 1 of each 21-day cycle
80 mg/m² IV on Day 1 of each 21-day cycle
130 mg/m² IV on Day 1 of each 21-day cycle
1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle
800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle
Overall Survival in PD-L1 Positive Participants
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Time frame: From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.
Overall Survival in the Intent-to-Treat (ITT) Analysis Set
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Progression-free Survival (PFS) in PD-L1 Positive Participants
Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Overall Response Rate (ORR) in PD-L1 Positive Participants
ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Progression-free Survival (PFS) in the ITT Analysis Set
Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Overall Response Rate (ORR) in the ITT Analysis Set
ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Duration of Response (DOR) in PD-L1 Positive Participants
DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Duration of Response in the ITT Analysis Set
DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
Time frame: Baseline and Cycles 4 and 6
Change From Baseline in EORTC QLQ-C30 Fatigue Score
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.
Time frame: Baseline and Cycles 4 and 6
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Gastric Cancer Module QLQ-STO22 (EORTC QLQ-STO22)
EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales: Dysphagia/odynophagia (4 items), Pain/discomfort (3 items), Dietary restrictions (5 items), Upper gastro-intestinal (GI) symptoms (3 items), Specific emotional problems (3 items) and 4 single items. Each question is answered on a scale from 0 (Not at all) to 4 (Very Much), where lower scores indicate fewer symptoms/better QoL. Raw scores were transformed to a scale from 0 to 100, where lower scores indicate better QoL. The QLQ-STO22 Index score is the mean of the 6 domain scores and 4 single items.
Time frame: Baseline and Cycles 4 and 6
Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)
The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
Time frame: Baseline and Cycles 4 and 6
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.
Time frame: From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.
Disease Control Rate in PD-L1 Positive Participants
Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator and the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Disease Control Rate in the ITT Analysis Set
Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Clinical Benefit Rate (CBR) in PD-L1 Positive Participants
Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Clinical Benefit Rate (CBR) in the ITT Analysis Set
Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Time to Response (TTR) in PD-L1 Positive Participants
Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Time to Response (TTR) in the ITT Analysis Set
Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
This study was conducted at 141 study centers in 13 countries across Asia, Europe, and North America. Adults with histologically confirmed, locally advanced unresectable or metastatic gastric or gastrooesophageal junction adenocarcinoma and no previous systemic therapy for advanced disease were recruited.
| Milestone | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Started | 501 | 496 |
| Received treatment | 498 | 494 |
| Completed | 1 | 0 |
| Not completed | 500 | 496 |
| Withdrew: Death | 397 | 431 |
| Withdrew: Study closed by sponsor | 77 | 38 |
| Withdrew: Withdrawal by subject | 20 | 17 |
| Withdrew: Lost to follow-up | 6 | 10 |
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Survival in PD-L1 Positive Participants | 17.2 (13.9 to 21.3) | 12.6 (12.0 to 14.4) |
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Survival in the Intent-to-Treat (ITT) Analysis Set | 15.0 (13.6 to 16.5) | 12.9 (12.1 to 14.1) |
Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) in PD-L1 Positive Participants | 7.2 (5.8 to 8.4) | 5.9 (5.6 to 7.0) |
ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
| percentage of participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Response Rate (ORR) in PD-L1 Positive Participants | 51.5 (45.4 to 57.5) | 42.6 (36.7 to 48.8) |
Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) in the ITT Analysis Set | 6.9 (5.7 to 7.2) | 6.2 (5.6 to 6.9) |
ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
| percentage of participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Response Rate (ORR) in the ITT Analysis Set | 47.3 (42.9 to 51.8) | 40.5 (36.2 to 45.0) |
DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Duration of Response (DOR) in PD-L1 Positive Participants | 10.0 (8.2 to 16.8) | 6.9 (5.7 to 8.5) |
DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Duration of Response in the ITT Analysis Set | 8.6 (7.9 to 11.1) | 7.2 (6.0 to 8.5) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
| score on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Global Health Status/QOL: Cycle 4 | 1.35 (-0.24 to 2.94) | -0.45 (-2.04 to 1.13) |
| Global Health Status/QOL: Cycle 6 | 0.93 (-0.71 to 2.57) | -1.58 (-3.24 to 0.07) |
| Physical Functioning: Cycle 4 | -2.47 (-3.77 to -1.18) | -3.92 (-5.21 to -2.62) |
| Physical Functioning: Cycle 6 | -2.76 (-4.22 to -1.30) | -5.22 (-6.69 to -3.75) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.
| score on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Cycle 4 | 1.75 (-0.09 to 3.60) | 3.07 (1.23 to 4.91) |
| Cycle 6 | 1.71 (-0.32 to 3.75) | 4.73 (2.68 to 6.77) |
EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales: Dysphagia/odynophagia (4 items), Pain/discomfort (3 items), Dietary restrictions (5 items), Upper gastro-intestinal (GI) symptoms (3 items), Specific emotional problems (3 items) and 4 single items. Each question is answered on a scale from 0 (Not at all) to 4 (Very Much), where lower scores indicate fewer symptoms/better QoL. Raw scores were transformed to a scale from 0 to 100, where lower scores indicate better QoL. The QLQ-STO22 Index score is the mean of the 6 domain scores and 4 single items.
| units on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Index Score: Cycle 4 | -1.71 (-2.77 to -0.66) | -0.61 (-1.66 to 0.45) |
| Index Score: Cycle 6 | -1.84 (-2.95 to -0.74) | -0.22 (-1.34 to 0.89) |
| Dysphagia/Odynophagia Scale: Cycle 4 | -2.78 (-3.99 to -1.57) | -1.27 (-2.48 to -0.06) |
| Dysphagia/Odynophagia Scale: Cycle 6 | -2.79 (-3.93 to -1.64) | -2.01 (-3.17 to -0.86) |
| Pain/Discomfort Scale: Cycle 4 | -6.88 (-8.39 to -5.36) | -4.64 (-6.16 to -3.13) |
| Pain/Discomfort Scale: Cycle 6 | -5.97 (-7.56 to -4.38) | -4.09 (-5.69 to -2.49) |
| Dietary Restrictions Scale: Cycle 4 | -0.31 (-1.75 to 1.12) | 0.61 (-0.82 to 2.05) |
| Dietary Restrictions Scale: Cycle 6 | -0.25 (-1.79 to 1.30) | 1.08 (-0.48 to 2.63) |
| Upper Gastro-Intestinal Symptoms: Cycle 4 | -3.14 (-4.40 to -1.87) | -1.54 (-2.80 to -0.28) |
| Upper Gastro-Intestinal Symptoms: Cycle 6 | -3.24 (-4.58 to -1.90) | -1.49 (-2.84 to -0.14) |
The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
| score on a scale | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Cycle 4 | 2.9 ± 15.62 | 0.8 ± 14.91 |
| Cycle 6 | 3.0 ± 16.38 | -0.8 ± 15.17 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.
| Participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Any TEAE | 495 | 486 |
| Any SAE | 211 | 179 |
Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator and the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.
| percentage of participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Disease Control Rate in PD-L1 Positive Participants | 88.3 (83.9 to 91.9) | 83.1 (78.1 to 87.3) |
Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.
| percentage of participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Disease Control Rate in the ITT Analysis Set | 89.8 (86.8 to 92.3) | 83.3 (79.7 to 86.4) |
Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.
| percentage of participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Clinical Benefit Rate (CBR) in PD-L1 Positive Participants | 65.0 (59.0 to 70.6) | 59.2 (53.1 to 65.1) |
Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.
| percentage of participants | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Clinical Benefit Rate (CBR) in the ITT Analysis Set | 63.1 (58.7 to 67.3) | 58.9 (54.4 to 63.2) |
Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Time to Response (TTR) in PD-L1 Positive Participants | 1.4 (0.9 to 11.3) | 1.4 (1.0 to 17.5) |
Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.
| months | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Time to Response (TTR) in the ITT Analysis Set | 1.4 (0.9 to 13.4) | 1.4 (1.0 to 17.5) |
Collected over From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab + Chemotherapy | 397/501 (79.2%) | 211/498 (42.4%) | 489/498 (98.2%) |
| Placebo + Chemotherapy | 431/496 (86.9%) | 179/494 (36.2%) | 485/494 (98.2%) |
| Event | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Platelet count decreasedInvestigations | 16/498 | 17/494 |
| PneumoniaInfections and infestations | 12/498 | 14/494 |
| AnaemiaBlood and lymphatic system disorders | 4/498 | 10/494 |
| DeathGeneral disorders | 10/498 | 5/494 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 4/498 | 7/494 |
| General physical health deteriorationGeneral disorders | 6/498 | 7/494 |
| VomitingGastrointestinal disorders | 7/498 | 5/494 |
| Decreased appetiteMetabolism and nutrition disorders | 7/498 | 5/494 |
| PyrexiaGeneral disorders | 6/498 | 6/494 |
| DiarrhoeaGastrointestinal disorders | 6/498 | 4/494 |
| Event | Tislelizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| NauseaGastrointestinal disorders | 248/498 | 237/494 |
| Decreased appetiteMetabolism and nutrition disorders | 202/498 | 207/494 |
| AnaemiaBlood and lymphatic system disorders | 197/498 | 202/494 |
| Platelet count decreasedInvestigations | 173/498 | 184/494 |
| VomitingGastrointestinal disorders | 176/498 | 178/494 |
| Neutrophil count decreasedInvestigations | 172/498 | 163/494 |
| Aspartate aminotransferase increasedInvestigations | 157/498 | 150/494 |
| DiarrhoeaGastrointestinal disorders | 134/498 | 144/494 |
| White blood cell count decreasedInvestigations | 120/498 | 136/494 |
| Alanine aminotransferase increasedInvestigations | 123/498 | 105/494 |
| Age, Categorical(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 340 | 313 | 653 |
| >=65 years | 161 | 183 | 344 |
| Age, Continuous(years) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Mean | 58.8 ± 11.07 | 59.7 ± 11.20 | 59.3 ± 11.14 |
| Sex: Female, Male(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Female | 155 | 150 | 305 |
| Male | 346 | 346 | 692 |
| Ethnicity (NIH/OMB)(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 |
| Not Hispanic or Latino | 492 | 474 | 966 |
| Unknown or Not Reported | 7 | 16 | 23 |
| Race/Ethnicity, Customized(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Asian | 376 | 372 | 748 |
| White | 116 | 107 | 223 |
| Not Reported | 8 | 16 | 24 |
| Other | 1 | 0 | 1 |
| Unknown | 0 | 1 | 1 |
| Geographic Region(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| China (including Taiwan) | 259 | 257 | 516 |
| Japan and South Korea | 117 | 115 | 232 |
| North America/Europe | 125 | 124 | 249 |
| Primary Tumor Location(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Stomach | 405 | 395 | 800 |
| Gastro-oesophageal junction | 96 | 100 | 196 |
| Other* | 0 | 1 | 1 |
| PD-L1 Expression(Participants) | Tislelizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| < 5% | 227 | 224 | 451 |
| ≥ 5% | 274 | 272 | 546 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 149 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Dec 2018 to primary completion in Feb 2023, 50 months.
Results were first posted in Feb 2025, 1 year 11 months after primary completion. A results delay was requested in Feb 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab